- Home
- TYGO vs AVTX Comparison
TYGO vs AVTX Comparison
Compare TYGO & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- AVTX
- Stock Information
- Founded
- TYGO 2007
- AVTX 2011
- Country
- TYGO United States
- AVTX United States
- Employees
- TYGO N/A
- AVTX N/A
- Industry
- TYGO Semiconductors
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- TYGO Technology
- AVTX Health Care
- Exchange
- TYGO Nasdaq
- AVTX Nasdaq
- Market Cap
- TYGO 116.0M
- AVTX 138.8M
- IPO Year
- TYGO N/A
- AVTX 2015
- Fundamental
- Price
- TYGO $2.57
- AVTX $13.85
- Analyst Decision
- TYGO Strong Buy
- AVTX Strong Buy
- Analyst Count
- TYGO 1
- AVTX 9
- Target Price
- TYGO $6.00
- AVTX $30.14
- AVG Volume (30 Days)
- TYGO 708.2K
- AVTX 440.9K
- Earning Date
- TYGO 11-05-2025
- AVTX 11-06-2025
- Dividend Yield
- TYGO N/A
- AVTX N/A
- EPS Growth
- TYGO N/A
- AVTX N/A
- EPS
- TYGO N/A
- AVTX N/A
- Revenue
- TYGO $74,405,000.00
- AVTX $441,000.00
- Revenue This Year
- TYGO $94.76
- AVTX N/A
- Revenue Next Year
- TYGO $23.23
- AVTX N/A
- P/E Ratio
- TYGO N/A
- AVTX N/A
- Revenue Growth
- TYGO 52.31
- AVTX N/A
- 52 Week Low
- TYGO $0.58
- AVTX $3.39
- 52 Week High
- TYGO $2.58
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- TYGO 75.36
- AVTX 69.84
- Support Level
- TYGO $2.33
- AVTX $12.41
- Resistance Level
- TYGO $2.58
- AVTX $14.18
- Average True Range (ATR)
- TYGO 0.20
- AVTX 1.02
- MACD
- TYGO 0.02
- AVTX 0.14
- Stochastic Oscillator
- TYGO 90.10
- AVTX 82.82
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).